Back

PRIME Education, Inc. (PRIME®)

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Protein Kinase Inhibitors
  • Tyrosine Kinase Inhibitors

New Horizons in CML: Applying the Latest Evidence and Leading Strategies for Treatment Decision-Making Into Clinical Practice

Staying current with the rapidly evolving treatment landscape in chronic myeloid leukemia (CML) is essential for care teams seeking to deliver the best possible outcomes for their patients. From choosing among multiple frontline tyrosine kinase inhibitors (TKIs), to interpreting molecular response milestones, to optimizing therapy in later lines, today’s decisions require nuanced understanding of the latest data, guidelines, and patient-centered strategies. Tune in to this video podcast where two nationally recognized CML experts will engage in a dynamic, evidence-based discussion covering emerging frontline treatment options, molecular monitoring to inform response and sequencing, newer-generation TKIs for resistant disease, and strategies to mitigate adverse events through dose optimization. Don’t miss this opportunity to update your clinical practice with evidence-based recommendations and share key strategies with their teams to improve CML care nationwide.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.5 creditsAAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Podcast / audio
  • includes On-demand / recorded video
  • Credit · Up to 0.5 credits
  • Commercial Support
  • Released
    Nov 20, 2025
  • Last day to claim credit
    Nov 20, 2026 6 weeks left